Do Traders Think CorMedix Inc (CRMD) Can Keep Climbing Thursday?

CorMedix Inc (CRMD) stock has gained 15.19% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

CorMedix Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRMD!

See Full CRMD Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CRMD Stock Today?

CorMedix Inc (CRMD) stock has risen 6.92% while the S&P 500 is down -0.25% as of 10:54 AM on Thursday, Mar 14. CRMD has gained $0.27 from the previous closing price of $3.90 on volume of 414,367 shares. Over the past year the S&P 500 has gained 31.46% while CRMD has gained 11.50%. CRMD lost -$0.86 per share in the over the last 12 months.

More About CorMedix Inc

Cormedix Inc is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has been in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical needs. Click Here to get the full Stock Report for CorMedix Inc stock.